Overview

Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)

Status:
Terminated

Trial end date:
2008-07-01

Target enrollment:
0

Participant gender:
All

Summary

Patients receiving a patient assistance program during therapy for Hepatitis C will be enrolled into this study. All patients will receive PegIntron and Rebetol (according to the label) and the patient assistance program, which includes (1) medications used for treatment (psychiatric medications); (2) other interventions (nurse support); and (3) educational literature. This study will be compared to similar studies from other clinics using various patient support programs for the purpose of designing future comparative phase IV studies.

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Interferon-alpha
Peginterferon alfa-2b
Ribavirin

Criteria

Inclusion Criteria:

- Patients with chronic hepatitis C naive to treatment

Exclusion Criteria:

- None